|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0729 - 0.0729|
|52 Week Range||0.0729 - 1.1000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company") announces that it has terminated the non-binding memorandum of understanding ("MOU") to acquire all the issued and outstanding shares of Tidal Care Inc. o/a Tidal Psychedelics ("Tidal") as disclosed in Mynds's March 16, 2022 press release, due to differences in the strategic direction of the proposed acquisition. Mynd has advised Tidal of ...
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, is pleased to announce that Dr. Wilfred Jefferies, Mynd's Chief Scientific Officer, has been inducted as a Fellow of the National Academy of Inventors. Globally, the most accomplished inve
Announced positive preclinical data in measuring dosing accuracy in psilocybins and psilocybin analogs. ...